Verition Fund Management’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $293K | Sell |
8,649
-4,713
| -35% | -$157K | ﹤0.01% | 1764 |
|
|
2026
Q1 | $402K | Sell |
13,362
-289,508
| -96% | -$9.31M | ﹤0.01% | 1669 |
|
|
2025
Q4 | $9.45M | Buy |
+302,870
| New | +$7.46M | 0.04% | 496 |
|
|
2025
Q3 | – | Sell |
-123,452
| Closed | -$2.17M | – | 3995 |
|
|
2025
Q2 | $2.07M | Buy |
123,452
+54,252
| +78% | +$875K | 0.01% | 1915 |
|
|
2025
Q1 | $1.06M | Buy |
+69,200
| New | +$1.24M | 0.01% | 2085 |
|
|
2023
Q2 | – | Sell |
-20,026
| Closed | -$177K | – | 2542 |
|
|
2023
Q1 | $177K | Buy |
20,026
+2,620
| +15% | +$25.9K | ﹤0.01% | 1798 |
|
|
2022
Q4 | $159K | Sell |
17,406
-875
| -5% | -$7.63K | ﹤0.01% | 1796 |
|
|
2022
Q3 | $148K | Sell |
18,281
-73,104
| -80% | -$646K | ﹤0.01% | 2552 |
|
|
2022
Q2 | $687K | Buy |
+91,385
| New | +$796K | 0.01% | 1240 |
|
|
2022
Q1 | – | Sell |
-32,986
| Closed | -$264K | – | 3029 |
|
|
2021
Q4 | $264K | Buy |
+32,986
| New | +$298K | ﹤0.01% | 2063 |
|
|
2021
Q3 | – | Sell |
-11,999
| Closed | -$119K | – | 2300 |
|
|
2021
Q2 | $119K | Buy |
+11,999
| New | +$127K | ﹤0.01% | 1697 |
|
|
2020
Q1 | – | Sell |
-40,383
| Closed | -$396K | – | 1046 |
|
|
2019
Q4 | $396K | Buy |
40,383
+6,625
| +20% | +$59.1K | 0.01% | 755 |
|
|
2019
Q3 | $232K | Buy |
33,758
+12,461
| +59% | +$95.5K | 0.01% | 902 |
|
|
2019
Q2 | $197K | Sell |
21,297
-77,136
| -78% | -$930K | 0.01% | 984 |
|
|
2019
Q1 | $1.54M | Buy |
+98,433
| New | +$1.74M | 0.06% | 282 |
|
|
2018
Q4 | – | Sell |
-113,217
| Closed | -$2.44M | – | 1246 |
|
|
2018
Q3 | $2.44M | Buy |
+113,217
| New | +$2.63M | 0.09% | 231 |
|
|
2018
Q1 | – | Sell |
-10,300
| Closed | -$195K | – | 1313 |
|
|
2017
Q4 | $195K | Sell |
10,300
-62,006
| -86% | -$933K | 0.02% | 817 |
|
|
2017
Q3 | $1.27M | Sell |
72,306
-290
| -0.4% | -$6.53K | 0.1% | 223 |
|
|
2017
Q2 | $2.41M | Sell |
72,596
-26,591
| -27% | -$823K | 0.23% | 71 |
|
|
2017
Q1 | $3.18M | Buy |
99,187
+75,435
| +318% | +$2.57M | 0.3% | 44 |
|
|
2016
Q4 | $861K | Sell |
23,752
-13,158
| -36% | -$525K | 0.07% | 323 |
|
|
2016
Q3 | $1.7M | Buy |
36,910
+7,445
| +25% | +$388K | 0.18% | 108 |
|
|
2016
Q2 | $1.48M | Buy |
29,465
+17,020
| +137% | +$906K | 0.19% | 115 |
|
|
2016
Q1 | $666K | Buy |
+12,445
| New | +$730K | 0.11% | 245 |
|
|
2015
Q4 | – | Sell |
-9,485
| Closed | -$536K | – | 599 |
|
|
2015
Q3 | $536K | Buy |
+9,485
| New | +$615K | 0.14% | 187 |
|
Other funds holding TEVA
HIIFS
PF
CI
MMH
MIFH
LIM
Verition Fund Management's TEVA Position: Q2 2026 in Review
Verition Fund Management reduced its Teva Pharmaceuticals (TEVA) stake by 35% in Q2 2026, selling an estimated $157K and leaving 8,649 shares worth $293K. The position accounts for ﹤0.01% of the portfolio, ranked #1764.
Verition Fund Management first reported a position in TEVA in Q3 2015 and has held it in 25 quarters since. The position peaked at $9.45M in Q4 2025. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.
- Verition Fund Management held 8,649 shares of Teva Pharmaceuticals worth $293K as of Q2 2026.
- Verition Fund Management sold 4,713 Teva Pharmaceuticals shares in Q2 2026, an estimated $157K.
- Teva Pharmaceuticals made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1764 holding.
- Verition Fund Management first reported a position in Teva Pharmaceuticals in Q3 2015 and has held it in 25 quarters since.
- Verition Fund Management's Teva Pharmaceuticals position peaked at $9.45M in Q4 2025.
- 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.
Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.